Stocklytics Platform
Asset logo for symbol IONS
Ionis Pharmaceuticals
IONS52
$48.00arrow_drop_up1.45%$0.69
Asset logo for symbol IONS
IONS52

$48.00

arrow_drop_up1.45%
Key Stats
Open$47.33
Prev. Close$47.31
EPS-2.67
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$6.90B
PE Ratio-
LOWHIGH
Day Range46.84
48.24
52 Week Range35.95
54.44
Ratios
P/B Ratio15.74
Revenue$787.64M
Operating M. %-125.12%
Earnings$0.00
Earnings Growth %-35.80%
EBITDA Margin %-45.02%
ROE %-98.27%
EPS-2.67
Fundamentals
RPS$5.40
Gross Profit$778.51M
EBITDA-$354.60M
Total Debt$1.97B
P/S Ratio7.7x
Enterprise to EBITDA-22.08
Profit Margin-49.54%
ROA-8.13%
Debt/Equity Ratio6.67%
Payout Ratio-
Industry average yield2.94%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

IONSarrow_drop_up1.46%
US Healthcare Sectorarrow_drop_up0.81%
US Marketarrow_drop_up1.43%
check_circle
IONS / Market
IONS exceeded the US Market which returned 1.43% over the last twenty four hours.
check_circle
IONS / Healthcare Sector
IONS exceeded the US Healthcare sector which returned 0.81% over the last twenty four hours.

Ionis Pharmaceuticals (IONS) Statistics

Ionis Pharmaceuticals Inc (IONS) is a biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics. The company was founded in 1989 and is headquartered in Carlsbad, California. Ionis has a diverse pipeline of drugs in various stages of development, targeting a range of diseases including neurological disorders, cardiovascular diseases, and cancer. The company's lead drug, Spinraza, is approved for the treatment of spinal muscular atrophy (SMA) and has generated significant revenue for Ionis. In addition to Spinraza, Ionis has a number of other drugs in clinical trials, including drugs for Huntington's disease, amyotrophic lateral sclerosis (ALS), and cardiovascular diseases.

When it comes to statistics, Ionis Pharmaceuticals Inc has shown impressive performance. The stock has exhibited strong growth over the years, outperforming the sector. As of the latest available data, Ionis Pharmaceuticals Inc has a market capitalization of $10.5 billion. The stock is trading at a price-to-earnings ratio of 26.5, which is below the sector average. This indicates that the stock may be undervalued compared to its peers. Ionis Pharmaceuticals Inc has a profit margin of 25.3%, which is higher than the sector average. This indicates that the company is able to generate a significant profit from its operations. Ionis Pharmaceuticals Inc also has a strong balance sheet, with a total debt of only $34 million. This low debt level indicates that the company has a good financial position and is not overly leveraged.

add Ionis Pharmaceuticals  to watchlist

Keep an eye on Ionis Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
How has Ionis Pharmaceuticals (IONS) stock's performance compared to its sector and the market over the past year?

Over the past year, Ionis Pharmaceuticals (IONS) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 23.49%, Ionis Pharmaceuticals has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 52.38%, it has fallen short of the market average. This comparison highlights Ionis Pharmaceuticals 's performance relative to both its sector and the overall market over the last year.

help
What is the PE ratio of Ionis Pharmaceuticals (IONS) stock?

The PE ratio for Ionis Pharmaceuticals (IONS) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.

help
What is the EPS of Ionis Pharmaceuticals (IONS) stock?

The Earnings Per Share (EPS) for Ionis Pharmaceuticals (IONS), calculated on a diluted basis, is -$2.67. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

help
What is the operating margin of Ionis Pharmaceuticals (IONS) stock?

The operating margin for Ionis Pharmaceuticals (IONS) is -125.12%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

help
What is the EBITDA of Ionis Pharmaceuticals (IONS) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Ionis Pharmaceuticals (IONS) is -$354.61M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

help
How much debt does Ionis Pharmaceuticals (IONS) have?

Ionis Pharmaceuticals (IONS) has a total debt of $1.98B. The net debt, which accounts for cash and cash equivalents against the total debt, is $1.62B.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level